Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma.

Djavaheri-Mergny M, Giuriato S, Tschan MP, Humbert M.

Cells. 2019 Jan 30;8(2). pii: E103. doi: 10.3390/cells8020103. Review.

2.

Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.

Torossian A, Broin N, Frentzel J, Daugrois C, Gandarillas S, Saati TA, Lamant L, Brousset P, Giuriato S, Espinos E.

Haematologica. 2019 Jul;104(7):1428-1439. doi: 10.3324/haematol.2017.181966. Epub 2019 Jan 24.

3.

Targeting Autophagy in ALK-Associated Cancers.

Frentzel J, Sorrentino D, Giuriato S.

Cancers (Basel). 2017 Nov 27;9(12). pii: E161. doi: 10.3390/cancers9120161. Review.

4.

[The yin and the yang of autophagy in cancer cells].

Joffre C, Djavaheri-Mergny M, Pattingre S, Giuriato S.

Med Sci (Paris). 2017 Mar;33(3):328-334. doi: 10.1051/medsci/20173303021. Epub 2017 Apr 3. Review. French.

5.

Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.

Mitou G, Frentzel J, Desquesnes A, Le Gonidec S, AlSaati T, Beau I, Lamant L, Meggetto F, Espinos E, Codogno P, Brousset P, Giuriato S.

Oncotarget. 2015 Oct 6;6(30):30149-64. doi: 10.18632/oncotarget.4999.

6.

Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Hoareau-Aveilla C, Valentin T, Daugrois C, Quelen C, Mitou G, Quentin S, Jia J, Spicuglia S, Ferrier P, Ceccon M, Giuriato S, Gambacorti-Passerini C, Brousset P, Lamant L, Meggetto F.

J Clin Invest. 2015 Sep;125(9):3505-18. doi: 10.1172/JCI78488. Epub 2015 Aug 10.

7.

Twenty years of modelling NPM-ALK-induced lymphomagenesis.

Giuriato S, Turner SD.

Front Biosci (Schol Ed). 2015 Jun 1;7:236-47. Review.

PMID:
25961699
8.

Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination.

Colomba A, Giuriato S, Dejean E, Thornber K, Delsol G, Tronchère H, Meggetto F, Payrastre B, Gaits-Iacovoni F.

Blood Cancer J. 2011 Jun;1(6):e21. doi: 10.1038/bcj.2011.19. Epub 2011 Jun 3.

9.

ALK+ALCLs induce cutaneous, HMGB-1-dependent IL-8/CXCL8 production by keratinocytes through NF-κB activation.

Dejean E, Foisseau M, Lagarrigue F, Lamant L, Prade N, Marfak A, Delsol G, Giuriato S, Gaits-Iacovoni F, Meggetto F.

Blood. 2012 May 17;119(20):4698-707. doi: 10.1182/blood-2011-10-386011. Epub 2012 Mar 6.

10.

Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.

Dejean E, Renalier MH, Foisseau M, Agirre X, Joseph N, de Paiva GR, Al Saati T, Soulier J, Desjobert C, Lamant L, Prósper F, Felsher DW, Cavaillé J, Prats H, Delsol G, Giuriato S, Meggetto F.

Leukemia. 2011 Dec;25(12):1882-90. doi: 10.1038/leu.2011.168. Epub 2011 Jul 22.

PMID:
21778999
11.

A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.

Chabot S, Jabrane-Ferrat N, Bigot K, Tabiasco J, Provost A, Golzio M, Noman MZ, Giustiniani J, Bellard E, Brayer S, Aguerre-Girr M, Meggetto F, Giuriato S, Malecaze F, Galiacy S, Jaïs JP, Chose O, Kadouche J, Chouaib S, Teissié J, Abitbol M, Bensussan A, Le Bouteiller P.

J Exp Med. 2011 May 9;208(5):973-86. doi: 10.1084/jem.20100810. Epub 2011 Apr 11.

12.

Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.

Giuriato S, Foisseau M, Dejean E, Felsher DW, Al Saati T, Demur C, Ragab A, Kruczynski A, Schiff C, Delsol G, Meggetto F.

Blood. 2010 May 20;115(20):4061-70. doi: 10.1182/blood-2008-06-163386. Epub 2010 Mar 11.

13.

Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.

Tran PT, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, Horng G, Bellovin DI, Giuriato S, Wang CS, Whitsett JA, Felsher DW.

PLoS One. 2008 May 7;3(5):e2125. doi: 10.1371/journal.pone.0002125.

14.

Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.

Giuriato S, Faumont N, Bousquet E, Foisseau M, Bibonne A, Moreau M, Al Saati T, Felsher DW, Delsol G, Meggetto F.

Cancer Biol Ther. 2007 Aug;6(8):1318-23. Epub 2007 May 29.

PMID:
17660712
15.

Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.

Lamant L, de Reyniès A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S, Brugières L, Gaulard P, Espinos E, Delsol G.

Blood. 2007 Mar 1;109(5):2156-64. Epub 2006 Oct 31.

16.

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW.

Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16266-71. Epub 2006 Oct 20.

17.

Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates.

Passegué E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL.

J Exp Med. 2005 Dec 5;202(11):1599-611.

18.

Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model.

Sander S, Bullinger L, Karlsson A, Giuriato S, Hernandez-Boussard T, Felsher DW, Pollack JR.

Oncogene. 2005 Sep 8;24(40):6101-7.

PMID:
16007205
19.

Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer.

Giuriato S, Rabin K, Fan AC, Shachaf CM, Felsher DW.

Semin Cancer Biol. 2004 Feb;14(1):3-11. Review.

PMID:
14757531
20.

SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3,4,5-trisphosphate levels.

Giuriato S, Pesesse X, Bodin S, Sasaki T, Viala C, Marion E, Penninger J, Schurmans S, Erneux C, Payrastre B.

Biochem J. 2003 Nov 15;376(Pt 1):199-207.

21.

How cancers escape their oncogene habit.

Giuriato S, Felsher DW.

Cell Cycle. 2003 Jul-Aug;2(4):329-32. Review.

PMID:
12851484
22.

Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.

Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW.

Blood. 2003 Apr 1;101(7):2797-803. Epub 2002 Nov 27.

23.

Conversion of PtdIns(4,5)P(2) into PtdIns(5)P by the S.flexneri effector IpgD reorganizes host cell morphology.

Niebuhr K, Giuriato S, Pedron T, Philpott DJ, Gaits F, Sable J, Sheetz MP, Parsot C, Sansonetti PJ, Payrastre B.

EMBO J. 2002 Oct 1;21(19):5069-78.

24.

SHIP2 overexpression strongly reduces the proliferation rate of K562 erythroleukemia cell line.

Giuriato S, Blero D, Robaye B, Bruyns C, Payrastre B, Erneux C.

Biochem Biophys Res Commun. 2002 Aug 9;296(1):106-10.

PMID:
12147234
25.

Production of phosphatidylinositol 3,4,5-trisphosphate and phosphatidic acid in platelet rafts: evidence for a critical role of cholesterol-enriched domains in human platelet activation.

Bodin S, Giuriato S, Ragab J, Humbel BM, Viala C, Vieu C, Chap H, Payrastre B.

Biochemistry. 2001 Dec 18;40(50):15290-9.

PMID:
11735411
26.

Phosphoinositides: key players in cell signalling, in time and space.

Payrastre B, Missy K, Giuriato S, Bodin S, Plantavid M, Gratacap M.

Cell Signal. 2001 Jun;13(6):377-87. Review.

PMID:
11384836
27.

The Src homology 2 domain containing inositol 5-phosphatase SHIP2 is recruited to the epidermal growth factor (EGF) receptor and dephosphorylates phosphatidylinositol 3,4,5-trisphosphate in EGF-stimulated COS-7 cells.

Pesesse X, Dewaste V, De Smedt F, Laffargue M, Giuriato S, Moreau C, Payrastre B, Erneux C.

J Biol Chem. 2001 Jul 27;276(30):28348-55. Epub 2001 May 10.

28.
29.

Microtubule integrity regulates src-like and extracellular signal-regulated kinase activities in human pro-monocytic cells. Importance for interleukin-1 production.

Schmid-Alliana A, Menou L, Manié S, Schmid-Antomarchi H, Millet MA, Giuriato S, Ferrua B, Rossi B.

J Biol Chem. 1998 Feb 6;273(6):3394-400.

30.

Tyrosine phosphorylation and relocation of SHIP are integrin-mediated in thrombin-stimulated human blood platelets.

Giuriato S, Payrastre B, Drayer AL, Plantavid M, Woscholski R, Parker P, Erneux C, Chap H.

J Biol Chem. 1997 Oct 24;272(43):26857-63.

Supplemental Content

Loading ...
Support Center